期刊文献+

线粒体解耦联蛋白2在宫颈癌中的作用及生物信息学分析 被引量:5

Role and bioinformatics analysis of UCP2 in cervical cancer
下载PDF
导出
摘要 目的:研究线粒体解耦联蛋白2(UCP2)对宫颈鳞癌增殖、凋亡、转移的影响。方法:通过质粒转染技术,下调宫颈癌细胞系中UCP2的表达,分别用MTT、流式细胞术、Transwell小室检测宫颈鳞癌细胞增殖、凋亡、侵袭、转移能力的变化;利用生物信息学的方法对UCP2蛋白进行生物信息学分析,并分析与之相互作用的蛋白。结果:(1)q RT-PCR和WB证实质粒转染后UCP2在宫颈癌细胞株中的表达较对照组明显降低。(2)MTT、凋亡、Transwell小室实验结果显示,下调UCP2后Si Ha细胞的增殖能力明显减弱,凋亡率增加,转移能力减弱(P<0.05)。(3)生物信息学分析显示UCP2蛋白定位于线粒体,可能存在多个磷酸化位点,且与多种蛋白相互作用,发挥生物学效应。结论:UCP2可能在宫颈癌的发生和发展中发挥重要作用,有望成为宫颈癌的早期诊断标志物和治疗的新靶点。 Objective To investigate the effect of UCP2 on cell proliferation, apoptosis, metastasis in cervical squamous carcinoma. Methods Plasmidmediated downregulation of UCP2 was obtained in cervical cancer cell lines. MTT, flow cytometry and transwell chamber assay were conducted to detect the ability of proliferation, apoptosis and metastasis. Characteristics of UCP2 protein was analyzed by hioinformatics methods. Results ( 1 ) UCP2 was verified to be downregulated by qRT-PCR and Western blotting assay. (2) MTT, apoptosis assay and transwell chamber assay showed that the proliferation of SiHa cell was significantly inhibited, and the apoptosis rate was significantly increased, and metastasis was markedly deduced (P 〈 0.05). (3) Bioinformatic analysis showed that UCP2 was located in mitochondria with several phosphorylation sites, and UCP2 interacted with other proteins to produce biological effects. Conclusion UCP2 may play an important role in the occurrence and development of cervical cancer, and it is expected to be a new target for the early diagnosis and treatment of cervical cancer.
出处 《实用医学杂志》 CAS 北大核心 2017年第1期91-94,共4页 The Journal of Practical Medicine
关键词 宫颈肿瘤 解耦联蛋白2 生物信息学 Cervical cancer Uncoupling protein 2 Bioinformatics
  • 引文网络
  • 相关文献

参考文献2

二级参考文献40

  • 1Jemal Ahmedin,Bray Freddie,Center Melissa M,Ferlay Jacques,Ward Elizabeth,Forman David.Global cancer statistics. CA: a cancer journal for clinicians . 2011
  • 2Mitsuro Kanda,Hanno Matthaei,Jian Wu,Seung–Mo Hong,Jun Yu,Michael Borges,Ralph H. Hruban,Anirban Maitra,Kenneth Kinzler,Bert Vogelstein,Michael Goggins.Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia[J].Gastroenterology.2012(4)
  • 3Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer [J]. Clin,2011, 61(2): 69-90.
  • 4Tewari KS, Sill MW, Long I-IJ 3rd,et al. Improved survival with bevacizumab in advanced cervical cancer [J]. N Engl Med, 2014,370 (8) : 734-743.
  • 5Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND 184 [J]. Gynecol Oncol, 2010, 116(2): 163-167.
  • 6Monk BJ, Pandite LN. Survival data from a phase /I, open- label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer [J]. Clin Oncol , 2011, 29(36): 4845.
  • 7Symonds P, Gourley C, Davidson S,et al. LBA25_PR- CIRCCa: A randomised double blind phase II trial of carboplatin-paelitaxel plus cediranib versus carboplatin-- paclitaxel plus placebo in metastatic/recurrent cervical cancer [J]. Ann Oncol, 2014,25 (suppl 4). doi: 10.1093.
  • 8Conesa-Zamora P, Torres-Moreno D, Isaac MA, et al. Gene amplification and immunohistochemical expression of ERBB2 and EGFR in cervical carcinogenesis. Correlation with cell- cycle markers and HPV presence [J]. Exp Mol Pathol, 2013, 95(2): 151-155.
  • 9Goncalves A, Fabbro M, Lhomm6 C, et al. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer [J]. Gynecol Oncol, 2008, 108(1) : 42-46.
  • 10Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open- label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer [J]. Clin Oncol, 2010, 28(22): 3562-3569.

共引文献23

同被引文献34

引证文献5

二级引证文献6

;
使用帮助 返回顶部